MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 534796 | Name: MS-818 free base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MS-818 free base is a bioactive chemical.

Chemical Structure

MS-818 free base
MS-818 free base
CAS#104966-11-2

Theoretical Analysis

MedKoo Cat#: 534796

Name: MS-818 free base

CAS#: 104966-11-2

Chemical Formula: C11H15N5O

Exact Mass: 233.1277

Molecular Weight: 233.28

Elemental Analysis: C, 56.64; H, 6.48; N, 30.02; O, 6.86

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
MS-818 free base; MS-818; MS 818; MS818
IUPAC/Chemical Name
5H-Pyrrolo(3,4-d)pyrimidin-5-one, 6,7-dihydro-6-methyl-2-(1-piperazinyl)-
InChi Key
MLVNBIZLVSIUJS-UHFFFAOYSA-N
InChi Code
InChI=1S/C11H15N5O/c1-15-7-9-8(10(15)17)6-13-11(14-9)16-4-2-12-3-5-16/h6,12H,2-5,7H2,1H3
SMILES Code
O=C1N(C)CC2=NC(N3CCNCC3)=NC=C21
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 233.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Sugaya K, Vaidya M. Stem Cell Therapies for Neurodegenerative Diseases. Adv Exp Med Biol. 2018;1056:61-84. doi: 10.1007/978-3-319-74470-4_5. PMID: 29754175. 2: Kanemura M, Abe M, Ueda M, Ueki M, Awaya A, Sato Y. MS-818 accelerates mobilization of endothelial progenitor cells and differentiation to endothelial cells. Endothelium. 2004 Sep-Dec;11(5-6):221-30. doi: 10.1080/10623320490904089. PMID: 15763941. 3: Sanjo N, Owada K, Kobayashi T, Mizusawa H, Awaya A, Michikawa M. A novel neurotrophic pyrimidine compound MS-818 enhances neurotrophic effects of basic fibroblast growth factor. J Neurosci Res. 1998 Dec 1;54(5):604-12. doi: 10.1002/(SICI)1097-4547(19981201)54:5<604::AID-JNR5>3.0.CO;2-W. PMID: 9843151. 4: Sugiyama N, Yoshimura A, Fujitsuka C, Iwata H, Awaya A, Mori S, Yoshizato H, Fujitsuka N. Acceleration by MS-818 of early muscle regeneration and enhanced muscle recovery after surgical transection. Muscle Nerve. 2002 Feb;25(2):218-29. doi: 10.1002/mus.10028. PMID: 11870690. 5: Jiang XM, Ohnishi A, Yamamoto T, Murai Y, Awaya A, Ikeda M. The effect of MS-818, a pyrimidine compound, on the regeneration of peripheral nerve fibers of mice after a crush injury. Acta Neuropathol. 1995;90(2):130-4. doi: 10.1007/BF00294311. PMID: 7484087. 6: Fukuyama R, Ohta M, Ohta K, Saiwaki T, Fushiki S, Awaya A. A synthesized pyrimidine compound, MS-818, promotes walking function recovery from crush injury of the sciatic nerve through its indirect stimulation of Schwann cells. Restor Neurol Neurosci. 2000;17(1):9-16. PMID: 11490072. 7: Watanabe S, Wang XE, Hirose M, Osada T, Yoshizawa T, Tanaka H, Itatsu T, Nakajima M, Yamamoto J, Miwa H, Miyazaki A, Awaya A, Sato N. A neurotrophic pyrimidine compound, MS-818, enhances EGF-induced restoration of gastric epithelial wounds in vitro. J Clin Gastroenterol. 1998;27 Suppl 1:S105-9. doi: 10.1097/00004836-199800001-00017. PMID: 9872506. 8: Yasuhara S, Kashiwagi S, Ito H, Awaya A. The neurotrophic pyrimidine heterocyclic compound MS-818 promotes the angiogenesis induced by basic FGF. Int J Clin Pharmacol Res. 1995;15(5-6):167-74. PMID: 8835614. 9: Yoshikawa M, Saura R, Mizuno K, Awaya A. The effect of MS-818, newly synthesized pyrimidine compound, on fracture repair. Kobe J Med Sci. 2000 Dec;46(6):265-82. PMID: 11501015. 10: Itoh S, Samejima H, Shinomiya K, Awaya A. The effect of neurotrophic pyrimidine heterocyclic compounds, MS-818 and MS-430, on the regeneration of injured peripheral nerves. Restor Neurol Neurosci. 1999;14(4):265-273. PMID: 12671247. 11: Mitsuyama T, Kawamata T, Yamane F, Awaya A, Hori T. Role of a synthetic pyrimidine compound, MS-818, in reduction of infarct size and amelioration of sensorimotor dysfunction following permanent focal cerebral ischemia in rats. J Neurosurg. 2002 Jun;96(6):1072-6. doi: 10.3171/jns.2002.96.6.1072. PMID: 12066909. 12: Torigoe K, Awaya A. A newly synthesized neurotropic pyrimidine compound, MS-818, may activate migratory schwann cells in peripheral nerve regeneration. Brain Res. 1998 Mar 23;787(2):337-40. doi: 10.1016/s0006-8993(97)01491-1. PMID: 9518680. 13: Williams JA, Day M, Heavner JE. Ziconotide: an update and review. Expert Opin Pharmacother. 2008 Jun;9(9):1575-83. doi: 10.1517/14656566.9.9.1575. PMID: 18518786. 14: Shimoda N, Mutou Y, Shimura N, Tsukimoto M, Awaya A, Kojima S. Effect of heterocyclic pyrimidine compounds on UVB-induced cell damage in human keratinocytes and on melanogenesis in mouse B16 cells. Biol Pharm Bull. 2010;33(5):862-8. doi: 10.1248/bpb.33.862. PMID: 20460767. 15: Captur G, Gatehouse P, Keenan KE, Heslinga FG, Bruehl R, Prothmann M, Graves MJ, Eames RJ, Torlasco C, Benedetti G, Donovan J, Ittermann B, Boubertakh R, Bathgate A, Royet C, Pang W, Nezafat R, Salerno M, Kellman P, Moon JC. A medical device-grade T1 and ECV phantom for global T1 mapping quality assurance-the T1 Mapping and ECV Standardization in cardiovascular magnetic resonance (T1MES) program. J Cardiovasc Magn Reson. 2016 Sep 22;18(1):58. doi: 10.1186/s12968-016-0280-z. PMID: 27660042; PMCID: PMC5034411. 16: Ohbayashi K, Inoue HK, Awaya A, Kobayashi S, Kohga H, Nakamura M, Ohye C. Peripheral nerve regeneration in a silicone tube: effect of collagen sponge prosthesis, laminin, and pyrimidine compound administration. Neurol Med Chir (Tokyo). 1996 Jul;36(7):428-33. doi: 10.2176/nmc.36.428. PMID: 8741371. 17: Koyama Y, Awaya A, Ishikawa N, Fujita S, Tomino I, Yokoyama K, Araki S, Takesue M, Kato K, Ishiguro M, Kitahara T, Kihara N, Baba A. Neurotropic pyrimidine heterocyclic compounds. II. Effects of novel neurotropic pyrimidine derivatives on astrocytic morphological differentiation. Biol Pharm Bull. 1997 Feb;20(2):138-41. doi: 10.1248/bpb.20.138. Erratum in: Biol Pharm Bull 1997 Jul;20(7):823. PMID: 9057974. 18: Baker-Jarvis J. Time-dependent entropy evolution in microscopic and macroscopic electromagnetic relaxation. Phys Rev E Stat Nonlin Soft Matter Phys. 2005 Dec;72(6 Pt 2):066613. doi: 10.1103/PhysRevE.72.066613. Epub 2005 Dec 22. PMID: 16486084. 19: Baker-Jarvis J, Kabos P, Holloway CL. Nonequilibrium electromagnetics: Local and macroscopic fields and constitutive relationships. Phys Rev E Stat Nonlin Soft Matter Phys. 2004 Sep;70(3 Pt 2):036615. doi: 10.1103/PhysRevE.70.036615. Epub 2004 Sep 29. PMID: 15524664. 20: Baker-Jarvis J, Riddle B, Janezic MD. Dielectric polarization evolution equations and relaxation times. Phys Rev E Stat Nonlin Soft Matter Phys. 2007 May;75(5 Pt 2):056612. doi: 10.1103/PhysRevE.75.056612. Epub 2007 May 25. PMID: 17677191.